Lazard Asset Management Portfolio holdings
AUM
$72.7B
1-Year Return
14.89%
This Quarter Return
+9.6%
1 Year Return
+14.89%
3 Year Return
+61.14%
5 Year Return
+112.7%
10 Year Return
+262.42%
AUM
$72.7B
AUM Growth
+$7.54B
(+12%)
Cap. Flow
-$4.12B
Cap. Flow
% of AUM
-5.67%
Top 10 Holdings %
Top 10 Hldgs %
23.55%
Holding
2,622
New
253
Increased
940
Reduced
728
Closed
298
Top Buys
| 1 |
Crown Castle
CCI
|
$544M |
| 2 |
Procter & Gamble
PG
|
$350M |
| 3 |
CSX Corp
CSX
|
$329M |
| 4 |
NVIDIA
NVDA
|
$233M |
| 5 |
GE Aerospace
GE
|
$200M |
Top Sells
| 1 |
NetEase
NTES
|
$433M |
| 2 |
HEICO
HEI
|
$339M |
| 3 |
American Electric Power
AEP
|
$337M |
| 4 |
Alibaba
BABA
|
$309M |
| 5 |
Prologis
PLD
|
$308M |
Sector Composition
| 1 | Technology | 27.05% |
| 2 | Financials | 13.73% |
| 3 | Industrials | 12.09% |
| 4 | Healthcare | 10.45% |
| 5 | Consumer Discretionary | 7.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1901
Brown & Brown
BRO
$31.3B
| $21K | ﹤0.01% |
196
-3,005
| -94% | -$322K |
|
1902
Equity Residential
EQR
$25.5B
| $21K | ﹤0.01% |
323
-10
| -3% | -$650 |
|
1903
Iron Mountain
IRM
$27.2B
| $21K | ﹤0.01% |
210
-283
| -57% | -$28.3K |
|
1904
Krystal Biotech
KRYS
$4.35B
| $21K | ﹤0.01% |
155
-249
| -62% | -$33.7K |
|
1905
Ultragenyx Pharmaceutical
RARE
$3.07B
| $21K | ﹤0.01% |
588
-33,455
| -98% | -$1.19M |
|
1906
Spectrum Brands
SPB
$1.38B
| $21K | ﹤0.01% |
411
-35,897
| -99% | -$1.83M |
|
1907
Douglas Elliman
DOUG
$257M
| $20K | ﹤0.01% |
8,946
+1,668
| +23% | +$3.73K |
|
1908
Dow Inc
DOW
$17.4B
| $20K | ﹤0.01% |
759
-5,963
| -89% | -$157K |
|
|
FSP
1909
Franklin Street Properties
FSP
$174M
| $20K | ﹤0.01% |
12,525
| – | – |
|
1910
Guaranty Bancshares
GNTY
$562M
| $20K | ﹤0.01% |
+483
| New | +$20K |
|
1911
Granite Ridge Resources
GRNT
$700M
| $20K | ﹤0.01% |
3,200
-117,932
| -97% | -$737K |
|
1912
Sibanye-Stillwater
SBSW
$6.08B
| $20K | ﹤0.01% |
2,864
| – | – |
|
1913
Amicus Therapeutics
FOLD
$2.46B
| $19K | ﹤0.01% |
3,488
-7,326
| -68% | -$39.9K |
|
1914
Invitation Homes
INVH
$18.5B
| $19K | ﹤0.01% |
597
-18
| -3% | -$573 |
|
1915
Ardelyx
ARDX
$1.57B
| $18K | ﹤0.01% |
4,655
-11,698
| -72% | -$45.2K |
|
1916
Geron
GERN
$893M
| $18K | ﹤0.01% |
13,123
-39,930
| -75% | -$54.8K |
|
1917
Immatics
IMTX
$761M
| $18K | ﹤0.01% |
3,350
-3,489
| -51% | -$18.7K |
|
1918
Kura Oncology
KURA
$713M
| $18K | ﹤0.01% |
3,234
-8,517
| -72% | -$47.4K |
|
1919
Agios Pharmaceuticals
AGIO
$2.09B
| $17K | ﹤0.01% |
534
-2,124
| -80% | -$67.6K |
|
1920
Apellis Pharmaceuticals
APLS
$3.55B
| $17K | ﹤0.01% |
1,024
-2,529
| -71% | -$42K |
|
1921
Vericel Corp
VCEL
$1.72B
| $17K | ﹤0.01% |
410
-29,239
| -99% | -$1.21M |
|
|
EXE
1922
Expand Energy Corporation Common Stock
EXE
$22.7B
| $17K | ﹤0.01% |
150
-1,105
| -88% | -$125K |
|
1923
Bank7 Corp
BSVN
$458M
| $16K | ﹤0.01% |
+402
| New | +$16K |
|
1924
Acme United Corp
ACU
$169M
| $15K | ﹤0.01% |
+365
| New | +$15K |
|
1925
GDS Holdings
GDS
$6.35B
| $15K | ﹤0.01% |
504
| – | – |
|